Zydus Cadila receives final nod from USFDA for Sevelamer Carbonate Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Aug 13, 2020 03:08 IST India Infoline News Service

Cadila Healthcare
Zydus Cadila has received final approval from the USFDA to market Sevelamer Carbonate Tablets (US RLD - Renvela Tablets) in the strength of 800 mg.

The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY2003-04.

Cadila Healthcare Ltd is currently trading at Rs387.40, up by Rs2.1 or 0.55% from its previous closing of Rs385.30 on the BSE. The scrip opened at Rs395 and has touched a high and low of Rs395.05 and Rs385.50 respectively.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity